NIH Sponsored Advanced Training Course
Rehabilitative and Regenerative Medicine for Minority Health and Health Disparities (REMEDY), a FRONTIERS Advanced Training Course, trains and mentors promising physician-scientists and other researchers from predominately underrepresented communities in sophisticated technologies in rehabilitation and regenerative research.
The purpose of this NICHD Continuing Education Training Program is to provide comprehensive and sophisticated training and state-of-the-art methods on bioengineering, cellular, molecular and genetic approaches for advancing the Frontiers in Rehabilitative and Regenerative Medicine for rectifying Minority Health and Health Disparities.
This NIH sponsored course target audience is young and promising faculty already involved in rehabilitation and regeneration investigations, as well as advanced postdoctoral fellows eager to learn about the newest findings and controversies. We intend to give students knowledge of laboratory techniques, career mentoring and the ethical-legal-societal impact of rehabilitative and regenerative research to greatly enhance their successful entry into this field or to strengthen the knowledge in this field.
REMEDY offers dynamic training courses that provide a fresh series of daily lecturers on emerging concepts, followed by extended discussion, laboratory research, technologically intense workshops and informal seminars over a week-long period. The primary aim is to educate and update rehabilitation and regeneration researchers on the implications of stem cells and tissue engineering for mechanistic discoveries and on designing improved strategies for rehabilitation discoveries, especially in the CNS and skeletal-muscular systems. This course provides an innovative educational opportunity to motivate biomedical trainees to pursue scientific careers in rehabilitation research. The courses are offered at Howard University in Washington, D.C., Morehouse School of Medicine in Atlanta, GA and Meharry Medical College in Nashville, TN.
The Stem Cells in Cancer Course will exclusively use human embryonic stem cell lines on the NIH Human Embryonic Stem Cell Registry.